Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. [electronic resource]
Producer: 20170804Description: 333-342 p. digitalISSN:- 1432-0843
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab -- administration & dosage
- Capecitabine -- administration & dosage
- Cisplatin -- administration & dosage
- Disease-Free Survival
- Drug Combinations
- Female
- Fluorouracil -- administration & dosage
- Humans
- Intestinal Neoplasms -- drug therapy
- Intestine, Small -- pathology
- Japan
- Leucovorin -- administration & dosage
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Organoplatinum Compounds -- administration & dosage
- Oxonic Acid -- administration & dosage
- Retrospective Studies
- Survival Rate
- Tegafur -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.